Current Opinion in Lipidology volume 28, issue 2, P186-192 2017 DOI: 10.1097/mol.0000000000000399 View full text
Lisa Christopher-Stine, Pari Basharat

Abstract: It is important for the reader to understand the clinical presentation of statin-associated immune-mediated myopathy and the difference in its clinical presentation to that of statins as direct myotoxins. Prompt recognition of such an entity allows the clinician to immediately stop the offending agent if it has not already been discontinued as well as to recognize that statin rechallenge is not a likely option, and that prompt treatment with immunosuppression and/or immunomodulation is usually of enormous bene…

expand abstract